Dosage Forms. Tablet, Immediate Release: 400 mg, 500 mg; Tablet, Extended Release: 400 mg, 500 mg, 600 mg; Capsule, Immediate Release: 200 mg, 300 mg
Common FDA Label Indication, Dosing, and Titration.
1. Osteoarthritis and general pain: Immediate release, 300-500 mg po bid-tid or 400-500 mg po bid; Extended release, 400-1000 mg po daily; max 1200 mg/d
2. Rheumatoid arthritis: Immediate release, 200-400 mg po bid-tid; Extended release, 400-1000 mg po daily; max 1200 mg/d
3. Juvenile rheumatoid arthritis: Extended release, Children 6-16 y old and 20-30 kg, 400 mg po daily; 31-45 kg, 600 mg po daily; 46-60 kg, 800 mg po daily; >60 kg, 1000 mg po daily
Off-Label Uses. None
MOA. Nonselective inhibitor of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) and reversibly alters platelet function and prolongs bleeding time.
Drug Characteristics: Etodolac
Medication Safety Issues: Etodolac
Drug Interactions: Etodolac
Adverse Reactions: Etodolac
Efficacy Monitoring Parameters. Decreased pain and improved range of motion.
Toxicity Monitoring Parameters. CBC, LFTs, SCr, fecal occult blood tests if chronic use, severe skin rash, black tarry stools, chest pains, yellowing of eyes of skin, change in urination.
Key Patient Counseling Points. Take with food or milk to decrease GI upset.
Clinical Pearls. Elderly patients are at increased risk of GI ulceration. Use lowest effective dose for shortest possible duration; after observing initial response, adjust dose and frequency to meet individual patient’s needs.